Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046767 | 0.94 | SHBG (0.46) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL14213248 | 0.91 | SHBG (0.38) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL10046744 | 0.91 | SHBG (0.38) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL7591262 | 0.83 | SHBG (0.53) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL30003742 | 0.80 | SHBG (0.63) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL2384360 | 0.80 | SHBG (0.63) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL9405316 | 0.79 | CA1 (0.44) | SHBGHMGB1CXCL12CYP2C9ALOX5 | |
| SCHEMBL12998649 | 0.77 | SHBG (0.59) | SHBGHSPA5HMGB1CXCL12AMY1A | |
| SCHEMBL69627 | 0.77 | SHBG (0.70) | SHBGHSPA5HMGB1CXCL12DHFR | |
| SCHEMBL20102186 | 0.77 | SHBG (0.55) | SHBGHSPA5HMGB1CXCL12DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642656-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | SHBG 470/4885HSPA5 3284/4885HMGB1 2292/4885 |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | SHBG 470/4885HSPA5 3284/4885HMGB1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.